1-11 of 11
Pierre Fumoleau
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Olivier Humbert, Jean-Marc Riedinger, Céline Charon-Barra, Alina Berriolo-Riedinger, Isabelle Desmoulins, Véronique Lorgis, Salim Kanoun, Charles Coutant, Pierre Fumoleau, Alexandre Cochet, François Brunotte
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5460–5468.
https://doi.org/10.1158/1078-0432.CCR-15-0384
Published: 14 December 2015
View article titled, Identification of Biomarkers Including <sup>18</sup>FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Open the PDF for Identification of Biomarkers Including <sup>18</sup>FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

>Expression profile of apoptosis genes in breast tumors over expressing survivin.

Frédérique Végran, Romain Boidot, Pierre Fumoleau, Lyse Hahnel, Muriel Cadouot, Sarab Lizard-Nacol, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): A82.
Published: 15 August 2014
View article titled, &gt;Expression profile of apoptosis genes in breast tumors over expressing survivin.
Journal Articles

>Gene expression changes after one course of chemotherapy in breast cancer

Romain Boidot, Frédérique Végran, Muriel Cadouot, Lyse Hahnel, Pierre Fumoleau, Sarab Lizard-Nacol, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): A83.
Published: 15 August 2014
View article titled, &gt;Gene expression changes after one course of chemotherapy in breast cancer
Journal Articles

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

Nicolas Isambert, Gilles Freyer, Sylvie Zanetta, Benoît You, Pierre Fumoleau, Claire Falandry, Laure Favier, Sylvie Assadourian, Karen Soussan-Lazard, Samira Ziti-Ljajic, Veronique Trillet-Lenoir
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1743–1750.
https://doi.org/10.1158/1078-0432.CCR-11-1918
Published: 14 March 2012
View article titled, Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer

Erica L. Mayer, Jean-Francois Baurain, Joseph Sparano, Lewis Strauss, Mario Campone, Pierre Fumoleau, Hope Rugo, Ahmad Awada, Oumar Sy, Antonio Llombart-Cussac
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6897–6904.
https://doi.org/10.1158/1078-0432.CCR-11-0070
Published: 31 October 2011
View article titled, A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
Open the PDF for A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer in another window
Journal Articles

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

Sylvain Ladoire, Laurent Arnould, Lionel Apetoh, Bruno Coudert, Francois Martin, Bruno Chauffert, Pierre Fumoleau, François Ghiringhelli
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2413–2420.
https://doi.org/10.1158/1078-0432.CCR-07-4491
Published: 15 April 2008
View article titled, Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3<sup>+</sup> Regulatory T Cells
Open the PDF for Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3<sup>+</sup> Regulatory T Cells in another window
Journal Articles

Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification

Laurent Arnould, Patrick Arveux, Jerome Couturier, Marion Gelly-Marty, Catherine Loustalot, Francette Ettore, Christine Sagan, Martine Antoine, Frederique Penault-Llorca, Berangere Vasseur, Pierre Fumoleau, Bruno P. Coudert
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6404–6409.
https://doi.org/10.1158/1078-0432.CCR-06-3022
Published: 01 November 2007
View article titled, Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification
Open the PDF for Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification in another window
Journal Articles

Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies

Véronique Diéras, Jacques Bonneterre, Valérie Laurence, Marian Degardin, Jean-Yves Pierga, Marie-Edith Bonneterre, Sandrine Marreaud, Denis Lacombe, Pierre Fumoleau
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6256–6260.
https://doi.org/10.1158/1078-0432.CCR-04-2316
Published: 06 September 2005
View article titled, Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies
Open the PDF for Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies in another window
Journal Articles

The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors

Godefridus J. Peters, Paul Noordhuis, Cornelis J. van Groeningen, Giuseppe Giaccone, Ulbe Holwerda, Daphne Voorn, Ad Schrijvers, Jan H. Schornagel, Jos H. Beijnen, Pierre Fumoleau, Jan H. M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (12): 4072–4076.
https://doi.org/10.1158/1078-0432.CCR-1076-03
Published: 24 June 2004
View article titled, The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors
Open the PDF for The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors

Christian Dittrich, Herlinde Dumez, Hilary Calvert, Axel Hanauske, Marije Faber, Jantien Wanders, Murray Yule, Miroslav Ravic, Pierre Fumoleau
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5195–5204.
Published: 12 November 2003
View article titled, Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors in another window
Journal Articles

A Phase II Study of Intraperitoneal Radioimmunotherapy with Iodine-131-labeled Monoclonal Antibody OC-125 in Patients with Residual Ovarian Carcinoma

Marc-André Mahé, Pierre Fumoleau, Michel Fabbro, Jean-Paul Guastalla, Patrick Faurous, Pierre Chauvot, Lucienne Chetanoud, Jean-Marc Classe, Philippe Rouanet, Jean-François Chatal
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 3249s–3253s.
Published: 01 October 1999
View article titled, A Phase II Study of Intraperitoneal Radioimmunotherapy with Iodine-131-labeled Monoclonal Antibody OC-125 in Patients with Residual Ovarian Carcinoma
Open the PDF for A Phase II Study of Intraperitoneal Radioimmunotherapy with Iodine-131-labeled Monoclonal Antibody OC-125 in Patients with Residual Ovarian Carcinoma in another window